Germany Sharpens Telemedicine Oversight While Cannabis Industry Expands

 Germany plans stricter cannabis telemedicine regulations, requiring in-person doctor visits and banning mail-order pharmacies, a move that risks driving users to the illegal market. The Federal Ministry of Health aims to tighten regulations on medical cannabis to limit online prescriptions and delivery services: Minister Nina Warken proposes banning both online prescriptions and shipping of medical cannabis to better control sales and ensure direct doctor-patient interaction, potentially negatively impacting patients while failing to address the underlying causes of current issues.

• Proposed cannabis regulations threaten online platforms, risking patient access and potentially increasing illegal market activity, prompting industry backlash.
  • DoktorABC advocates for patient rights against proposed restrictions on cannabis prescriptions, warning of a two-tier healthcare system in Germany.
  • Simone Borchardt, health policy spokeswoman for the CDU/CSU, visited medical cannabis company Grünhorn in Leipzig and advocated for low-threshold access, even for those with sleep disorders. She emphasized that dispensing must be handled by pharmacy’s trained staff.
  • Patients warn that  restricting digital cannabis therapy risks pushing them back to illegal markets, threatening health and safety.
  • SPD health policymakers criticize draft bill amendments, emphasizing patient access and opposing online prescriptions for medical cannabis without doctor contact.
    • Kristine Lütke from Free Democratic Party believes a complete ban on remote prescription and mail order for cannabis flowers is an economic stimulus program for the black market.
    • Peter Homberg anticipates significant changes to the draft bill restricting cannabis telemedicine and mail-order pharmacies in Germany.
    • Bavarian government demands stricter cannabis prescription regulations, requiring personal doctor contact and banning online sales for medical cannabis.
    • A Bloomwell survey reveals restricting digital cannabis therapy risks pushing patients back to illegal markets, impacting health and safety.
• Concerns raised about the complexity of cannabis distribution and the need for more licensed clubs to combat illegal markets. Optimism remains for future cannabis model projects and potential for medical cannabis to become over-the-counter in Germany.
  • Germany has approved 293 cannabis cultivation clubs, allowing collective cultivation and distribution to members under regulated conditions.
  • Germany’s largest cannabis association, Mariana Cannabis Social Clubs Deutschland e.V., claims nearly 18,000 members and 180 branch clubs, yet only a fraction are officially registered, and just one has obtained an official cultivation license.
  • Criticism of the medical cannabis act amendment for stigmatizing users and inadequate regulation of remote prescribing and advertising practices by the Green Party.
• The CanG evaluation is being expanded, with the first report expected in early October. This planned interim report will examine the law’s impact on multiple areas, including health and youth protection, as well as road traffic safety.
  • Cannabis consumption trends remain stable; home cultivation is affordable, but licensed associations are insufficient to meet demand.
• Pharmacies can be prosecuted if they supply cannabis prescriptions issued via platforms without proper verification, according to a legal report commissioned by the Association of Cannabis Supplying Pharmacies (VCA).
• Health insurance companies will stop reimbursing cannabis flowers, citing concerns over increased use and associated health risks.
• ABDA supports price controls on medicinal cannabis; concerns over potential exclusion from reimbursement by health insurance companies.
• KKH’s claim of increased cannabis addiction post-decriminalization lacks evidence; rising diagnoses may reflect better reporting, not actual addiction increase.
• Legal opinion confirms approval of scientific cannabis pilot projects in Germany under current law, supporting health and market displacement insights.
• BDCan advocates for balanced cannabis regulations ensuring patient care, preventing abuse, and maintaining access to medical cannabis products.

 Imports of medical cannabis totalled 43.3 tonnes in the second quarter, a 6% increase versus the previous record in the first quarter: over 160 tonnes could be imported in 2025. Following legalisation medical cannabis extract prescriptions increased 33% in Q1 2025. The number of cannabis pharmacies increase fivefold within a year; as prices drop, market competition intensifies, and regulatory stability is crucial for patient care.

• However, industry operators are worried about medical cannabis market oversupply, falling prices, increased competition, and a shift towards consolidation among pharmacies.
• Cantourage achieved record sales of EUR 27.9 million in Q2 2025, surpassing last year’s total revenue by over 130%.
• SOMAÍ Pharmaceuticals launched the Senses product line, enhancing patient experience with terpene-enriched oral extract solutions for cannabis-based therapies.
• Canify AG launches “Craft” and “Ghostdrops” premium cannabis flower categories for tailored therapy and high-quality standards in pharmacies.
• SYNBIOTIC expects sales to triple by 2027, focusing on medical cannabis and industrial hemp growth markets.
• BDCan advocates for balanced cannabis regulations ensuring patient care, preventing abuse, and maintaining access to medical cannabis products.

 Subsurface drip irrigation reduces water use, weed infestation, and increases yield and CBD concentration in outdoor cannabis cultivation.

• Cannabinoid Hyperemesis Syndrome (CHS) increases with cannabis legalization; requires abstinence for diagnosis and treatment; poses diagnostic challenges.
• A survey conducted by the Healthcare Center for the Prevention of Cannabis Infection in Hanover has shown that more and more people are seeking medical treatment for mental health problems caused by cannabis use. Young people are particularly affected.

 United States: Cannabis Reform Stalls Under Trump Despite Overwhelming Public Support and Market Growth

 Nine in ten Americans support marijuana legalization, with bipartisan majorities favoring both medical and recreational use, according to a Pew poll.

• DEA’s marijuana rescheduling process remains stalled under Trump, with updates expected from Acting Administrator Robert Murphy in 90 days.
  • Terrance Cole confirmed as permanent DEA administrator, with the rescheduling process now under his authority.
  • A harsh Washington Post column argues Trump should halt Biden’s plan to reschedule marijuana, citing concerns about addiction, crime, and social issues.
  • Mike Tyson urges Trump to fulfill Biden’s cannabis reform pledge, advocating for clemency and banking access for cannabis businesses.
  • Anti-marijuana group launches a six-figure TV ad campaign urging Trump not to reschedule cannabis.
  • Trump administration targets California cannabis farms with immigration raids, causing panic among farmworkers and industry stakeholders.
    • ICE raided Glass House Brands, a major cannabis operator, sparking fear and confusion in California’s legal cannabis industry.
• New Yorkers express growing concerns over marijuana legalization, particularly regarding safety, public use, and illegal dispensaries.
• Former hemp-business partners of State Rep. John Bell allege he threatened to use his “power and influence” unless they paid him $1.6 million.
• Converted medical marijuana dispensaries can begin selling recreational weed in Delaware as early as August, with local governments able to implement stricter regulations.
• Kentucky medical cannabis companies sue over allegedly unconstitutional licensing process, seeking to overturn the state’s program rollout.
• DEA Administrator Cole’s strategic priorities exclude marijuana rescheduling, contradicting his earlier pledge during the confirmation hearing.
• Jersey government finalizing a ban on medicinal cannabis advertising due to safety concerns and a black market in prescription drugs.
• A bipartisan coalition of 32 state and territorial attorneys general urged Congressional leaders to pass the SAFER Banking Act.

 U.S. cannabis sales projected to reach $50–55 billion by 2030, with ~9% annual growth. Key growth markets include New York (due to retail licensing) and Ohio (driven by medical-to-adult-use market conversion).

• The legal New York marijuana market stands out among states that have legalized adult-use cannabis.
  • New survey shows New York cannabis consumers prioritize price, effects, and trust in products from licensed dispensaries.
  • At least 47 cannabis dispensaries opened too close to schools in New York after the attorney questioned regulators’ buffer zone measurement methods.
• Mood-boosting non-alcoholic drinks are trending, blending wellness with enjoyment in bars and restaurants.
  • Collective Project launched hemp-derived THC beverages in 25 U.S. states, expanding its product line and direct-to-consumer shipping.
• Chinese crime rings are undermining Michigan’s legal marijuana market through illegal operations that impact legitimate businesses.
  • TerrAscend plans to exit Michigan market, closing stores and reducing workforce to focus on core Northeastern markets.
• Big Alcohol explores cannabis drinks as traditional sales decline, with Constellation Brands and Pernod Ricard considering investments.
• States with legal cannabis saw $60,327 higher home value growth from 2009 to 2024 compared to states where cannabis remains illegal.
• Survey reveals cannabis-infused edibles are most popular in New York, surpassing vapes and flower among consumers’ preferences.
• Leafwell introduces an innovative Cannabis Care Program offering members clinical support and exclusive nationwide dispensary discounts.
• Neurogan launched the USA’s strongest full-spectrum CBD gummy, with potency verified by third-party testing.
• Cresco Labs is divesting its cultivation and manufacturing assets in California as part of a strategic restructuring plan.

Long-term cannabis use for medical symptoms may increase the risk of cannabis use disorder compared to recreational use. A clinical trial found 13% of participants met criteria for cannabis use disorder after 12 weeks.

• Cannabis reduces migraine symptoms in first placebo-controlled trial, with patients experiencing greater relief from pain and other symptoms than those receiving placebo.
• Study finds cannabidiol shows no acute effects in youth with alcohol use disorder, with no significant changes in neural, psychological, physiological, or behavioral outcomes.
• Cigarette smoking continues to decline while cannabis and vaping usage rise among young adults; alcohol use remains stable.
• Medical cannabis use significantly reduces healthcare utilization and improves quality of life for chronic pain patients.
• Research shows heating cannabis in vaporizers at 190°C for 70 seconds does not significantly reduce microbial populations or enhance recovery rates.
• Δ8-THC shows similar pharmacology to Δ9-THC but with lower potency and distinct metabolic pathways affecting its effects.
• Identified an X-linked gene, ACS, as a candidate for sex determination in cannabis and hop, linked to ethylene production.
• Standardized methods for assessing trichome density in Cannabis sativa are crucial for optimizing cannabinoid production and quality control.

 Australia’s Cannabis Growth Meets Rising Regulatory Scrutiny

 AHPRA (Australian Health Practitioner Regulation Agency) is cracking down on questionable prescribing with the launch of new guidance, amid concerns ‘profits are being prioritised over patient safety’.

• Some practitioners linked to Montu’s telemedicine platform Alternaleaf have issued more than 10,000 medicinal cannabis prescriptions in just six months, it can be revealed as Australia’s health watchdog announces a major crackdown.
• The Office of Drug Control has taken an average of 16 months to assess medicinal cannabis licence applications since 2022, data has shown.
• Australia’s TGA launches public consultation on unapproved medicinal cannabis products due to safety concerns and regulatory oversight issues.

 Thai cannabis imports surge, threatening local Australian growers, prompting calls for government intervention and import tax measures.

• ECS Botanics; Q4 FY25 investor update; continued growth in B2C sales and record flower production. It also launched Terphogz premium flower strains in June, further enhancing its branded offerings.
• Bioxyne achieved a 720% stock gain, leading ASX biotech, driving growth into FY26 and expanding European operations.
• Aurora reduces the price of its Equiposa Cannabis flos 8/8 by 50%, improving availability and lowering pharmacy shelf prices.
• Cannatrek has been fined $19,800 by the Office of Drug Control for allegedly breaching its medicinal cannabis licence.
• Integrative healthcare business, The New Clinic, has launched a division aimed at supporting patients who are “slipping through the cracks”.
• Cann Group seeks debt restructuring, reports record production, and aims for an EBITDA-positive outcome in FY2026.
• Montu faces scrutiny over high-volume prescriptions, alleged unsafe practices, and profit-driven culture amid rising medicinal cannabis industry concerns.
• MediCann has released results from a preclinical trial suggesting cannabinoid formulas may help reduce neuroinflammation after concussion.
• MedTEC Pharma is dropping its own-branded product range amid concerns it can not sell sufficient volumes to remain price competitive.
• CherryCo sales dropped 35% in FY26’s first quarter due to increased competition in the budget flower sector.
• Spring Sciences Australia plans IPO on ASX to raise capital for expansion and shareholder returns, prospectus expected in October.

 Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol.

• The effects of orally ingested Delta-9-Tetrahydrocannabinol on drivers’ hazard perception and risk-taking behaviours*.*
• Survey explores prescription and nonprescription drug use among people with eating disorders.
• A positive case report highlights the therapeutic potential of Argent’s (ASX:RGT) cannabinoid therapy CannEpil in treatment-resistant epilepsy
• A new clinical trial at Southern Cross University is looking at improving anxiety management in adults with autism.

United Kingdom: Fresh Investment Wave as Brexit Reset Threatens CBD Standards

 Starmer’s “Brexit reset” may align UK CBD regulations with EU, impacting approvals and industry stability amid ongoing negotiations.

• Trip drink’s advert banned for unauthorized health claims about calming and stress relieveng effects; The Advertising Standards Authority ruled that the ad must not appear again in the same form.
• Legalisation of cannabis in US driving soaring rates at UK border, as the Border Force credits the increase in drugs to changes in American law. It made 34,446 seizures last year, totalling nearly 80,000kg
• Releaf emphasizes quality consultations amid rising demand for medical cannabis, ensuring patient safety and adequate appointment times.
• Isle of Man aims to become a leader in medicinal cannabis, creating jobs and diversifying its economy through regulation and innovation.

 Prescriptions for medicinal cannabis products are increasing, raising concerns about inadequate communication and oversight among healthcare providers. Between April 2023 and March 2024, private clinics dispensed about 346,600 items of unlicensed cannabis-based products for medicinal use (CBPMs), up from 150,527 the previous year; a 130% increase

• Grow Group UK has restructured its distribution operations by acquiring Avida Medical and launching a fully owned service platform, marking the end of its partnership with IPS. Grow now operates independently, streamlining its supply chain under full control.
• Curaleaf acquires full ownership of Curaleaf International, without identifying the minority partner in any public filings or announcements. This acquisition strengthens the company’s control and strategic positioning in European markets.
• Spanish CBD cosmetics brand Beemine Lab partners with LEVA Clinic to assist individuals suffering from chronic pain, enhancing support and treatment options.
• BrewDog co-founder Martin Dickie invests £20 million to establish Waterside Pharmaceuticals as a UK leader in medical cannabis production.
• Goodrays raised €5.7 million for CBD drinks, appointed Liquid Death‘s Ben Dando as Managing Director, and expanded retail partnerships
• Ananda Pharma aims to replicate GW Pharmaceuticals’ success with its CBD drug MRX1 amid funding challenges in the market.
•  GrowLab Organics received licensing approval, set to export in 2026, exemplifying the potential for future cannabis market entrants.

Assessment of the Global Drug Policy Index’s validity and reliability across 30 countries, addressing drug policy measurement challenges.

• The Care Quality Commission has identified fraudulent activity involving doctors’ identities, soaring numbers of prescriptions for cannabis based products, and prevention of future death reports related to drug use as key regulatory issues it faced last year.

Canada’s Cannabis Crossroads: Trim the Red Tape or Choke the Growth?

 On July 9, the Treasury Board of Canada announced a regulatory review initiative. Over the next two months, ministers across federal agencies will examine regulations within their portfolios and work to eliminate outdated or duplicated requirements. It stands as an opportunity to modernize cannabis regulations, reducing operational costs for businesses, addressing policy misalignment and boosting investments and innovations.

• Experts warn surging THC levels are fuelling growing health risks and say stronger regulation is urgently needed.

 Area planted for hemp flowers in Canada nearly quintupled in 2024, hitting 4,607 hectares, signaling a possible resurgence for CBD and other hemp-derived.

• High Tide secures $30 Million investment from Cronos Group to fuel expansion, and plans to grow beyond 300 Canadian locations with fresh capital injection.
  • High Tide surpassed 2 million cannabis loyalty members in Canada.
• Cannara reports record Q3 2025 revenue, EBITDA, and free cash flow, hits 50,000 kg capacity goal early, and secures 5 vape SKUs for Quebec launch.
  • Cannara secures 5 key listings in Québec’s new vape cartridge category, including soon-to-be-released live rosin vapes.
• Rapid Dose Therapeutics Corp, a Canadian biotechnology company announced the launch of a new significant harm reduction initiative aimed at addressing the devastating opioid crisis gripping Canada’s First Nations communities.
• In Q2 2025, Tilray reports a $1.27 billion net loss as revenue declines and gross profit decreases from the previous year.
• Avant Brands reports Q2 2025 financial results with 3% revenue growth and sixth consecutive quarter of positive Adjusted EBITDA.
• HYTN Innovations received a cannabis drug license, enabling the development and distribution of prescription cannabinoid-based pharmaceuticals in Canada.
• Pure Sunfarms introduces windowed packaging for cannabis, enhancing consumer experience and transparency in product quality across Canada.
• Village Farms expands cannabis cultivation by converting 550,000 sq. ft. greenhouse, adding 40 tonnes annual production capacity by 2026.
• MediPharm Labs expands leading CBN Oil portfolio with the launch of new nighttime inhaler
• Uncover the financial impact of medical cannabis registration Veterans Affairs Canada, supporting veterans with $1.1 billion in reimbursements.

Investigated total THC variability in dried cannabis across cultivars, plant strata, and individual plants, highlighting significant measurement discrepancies.

• Environmental impacts of cannabis production are of increasing concern because it is a newly legal and growing industry. Although a handful of studies have quantified the impacts of indoor production, very little is known about the impact of outdoor.
• Fusarium species infecting greenhouse-grown cannabis (Cannabis sativa) plants demonstrate potential for mycotoxin production in inoculated inflorescences and natural inoculum sources.
• Cannabis use linked to mental health risks; cannabidiol effective for epilepsy; caution advised for adolescents and pregnant women.

Brazil Cuts Prices, Builds Databases, and Eyes a R$15B Future

 Santa Catarina government decree limits local cannabis producers, potentially increasing government costs by 60% and restricting patient access.

• Global regulations on semi-synthetic cannabinoids address health concerns and market growth, influencing Brazil’s industrial hemp regulation.

 Brazil’s medicinal cannabis market expected to reach R$15 billion by 2034 following regulatory changes and broader therapeutic applications.

• Associative market treats 130,742 medical patients: 50.3% women, 49.5% men, ages 6 months to 101 years. • 193,872 bottles of medicinal cannabis dispensed annually; 651 employees and 3,611 prescribing professionals across all states. 60.72% of patients grow their own plants.
• Prati-Donaduzzi cuts cannabidiol prices by up to 40% starting July 1, 2025, improving access for patients with chronic and neurological conditions.
• Blis app facilitates legal access to medical cannabis in Brazil, exceeding 300,000 users and managing Latin America’s largest cannabis database.
• Civil engineer establishes pioneering company to advance hempcrete use in Brazil, despite lack of regulation.

 UFV project aims to revolutionize hemp cultivation, drawing interest from the US, China, and Europe through innovative techniques and sustainability practices..

• Brazil launches first national mapping of cannabis researchers and institutions to bolster scientific efforts and inform public policies.

From Grey Zone to Green Economy: South Africa’s Cannabis Industry at a Crossroads

DTIC plans to overhaul cannabis laws by 2027, with extensive stakeholder consultation and a new commercial framework proposed.

• The South African Cannabis Clubs Alliance launched to unify cannabis clubs in South Africa for legal recognition and to advocate for self-regulated club legislation.
• Regulations for the Cannabis Act will be finalized by March 2026, pending feedback from multiple government departments.
• South Africa’s cannabis policy aims to create a $770,000 USD economic boost and 100,000 jobs by 2026/27, though it faces significant regulatory challenges.
• Western Cape’s CanPlan focuses on hemp trials and knowledge transfer, collaborating with the Agricultural Research Council to develop the hemp industry.
• Harambe Solutions advocates for private cannabis clubs as constitutional rights, emphasizing community, harm reduction, and self-regulation amidst legal challenges.
• South African Health Products Regulatory Auhority is refining cannabis regulations to improve patient access, standardization, and implement digital systems for efficient assessments.

 South Africa legalized recreational cannabis in 2018, establishing regulations for personal cultivation and use. Meanwhile, medicinal cannabis production is growing, with exports increasing from 587 kg in 2020 to 4,220 kg in 2021 and 8,505 kg in 2023.

• Agri-tech is enhancing South Africa’s cannabis industry by improving efficiency, quality, and job creation while addressing humidity challenges through advanced technology.
• Labat Africa is selling cannabis assets amid operational issues, focusing on transforming into a tech company, and facing compliance challenges.

From Reform to Rejection: Israel’s Cannabis Law Faces Political Pushback

 Health Minister Bosso demands that the cannabis law be halted. In a scathing letter, he criticizes key provisions, including the return of private doctors and the exclusion of CBD. He states that the proposal is “immature” and its integration with the drug ordinance is “poorly constructed.”

• Medical Cannabis Law approved in committee; includes prescription authority for family doctors and government funding for epilepsy patients’ treatment.
  • Ministry of Health announces tender for new Director of Medical Cannabis Division after Yuval Landschaft’s departure; applications due July 7, 2025.
• Israeli ombudsman upheld the rejection of high tariffs on Canadian cannabis, allowing Finance Minister’s veto against proposed import tax. Decision benefits 130,000 patients, ending months of uncertainty in the industry over the future of Canadian imports.
• Finance Minister Bezalel Smotrich previously rejected tariffs of up to 165% on Canadian medical cannabis, concluding a process initiated due to allegations of dumping.
  • David Vaknin secretly financed Emerald Leaves, claiming debts of 15 million shekels despite having a criminal record in the cannabis industry.

 Syqe Medical laid off 32% of employees, focusing on clinical trials and seeking FDA approval for its cannabis inhaler.

• Surge in anonymous cannabis products in Israel due to regulatory changes, raising concerns about quality and transparency for patients.
• Innocan has applied to list its Common Shares and Warrants on the Nasdaq capital market under the symbols “INNP” and “INNPW”, respectively.

 Cannabis oil is as safe and effective as monotherapy for autistic children, with no significant differences in efficacy.

Spain’s Legal Storm and Industry Shakeup

 At least five cannabis user associations in Barcelona have reportedly been closed after receiving a notice from the City Council months ago requiring them to temporarily close. More than thirty associations received this notice last year.

• Barcelona’s inspections on grow shops spark controversy, seen as unjustified criminalization and a threat to legal commerce and rights.
• Judicial ruling states mere presence of drugs in drivers does not prove impairment impacting traffic drug control measures, as saliva tests do not determine when the consumption took place, whether prior to driving or even on the same day, nor the intensity or effects of the substances.

Spanish holding Torreal increases stake in EU-GMP grower Linneo Health to 50.8%, enhancing control amid capital injections and strategic market expansion plans.

• AEMPS renewed Cannaflos Genetics S.L.‘s commercial multiplication authorization for unique medical cannabis genetics and tissue culture services.
• Hemp cultivation could justify defense spending, promoting sustainability and strategic autonomy while addressing agricultural and environmental challenges.
• JuicyFields scam continues with Viktor promoting new investment schemes despite Europol’s arrests and ongoing investigations into the fraud.

Cannabis Reform in Switzerland: Patients Demand Access, Industry Pushes Forward

 Patients demand better medical cannabis access in Switzerland, urging lawmakers to address high costs and low prescriber interest: despite legal amendments, access to medical cannabis remains unsatisfactory due to high prices and limited prescriber interest.

• Campaigners are calling for mandatory reimbursement of prescriptions and options for collective cultivation to meet patients’ needs.

 Cronos Group expands distribution of Peace Naturals medical cannabis in Switzerland through partnership with Dascoli Pharma AG

• Canexis Pharma received EU GMP Part I manufacturing authorization for bulk medicinal products.

 New research explores cannabis aroma and flavor, emphasising the role of terpenes and how genetics and cultivation practices impact them.

• Proximity to marijuana dispensaries correlates with lower opioid prescription rates, suggesting potential substitution effects for pain management.

Licensed but Illicit: Portugal’s Cannabis Industry Under Scrutiny

Portuguese authorities have uncovered a disturbing trend in the country’s medical cannabis industry. Two recent operations—Erva Daninha in May and Ortiga in July—have exposed criminal networks using licensed pharmaceutical firms as fronts for large-scale drug trafficking.

• In Erva Daninha, police seized over 7 tons of cannabis and arrested five individuals linked to an international scheme that relied on falsified export documents. Just weeks later, Ortiga led to the arrest of two foreign nationals and the seizure of an additional 2 tons of cannabis, once again tied to companies operating under the guise of legal medicinal activity.
• New Portuguese Cannabis Industry Association (APIC) held its first open assembly yesterday. ******Created with the mission of “representing the industry before regulatory bodies and policymakers, ensuring continuous and constructive dialogue,” APIC aims to protect its interests and promote the medicinal cannabis industry in Portugal and internationally.

 Portuguese entrepreneur Marta Vinhas founded Sensihemp in 2021, focusing on hemp for sustainable, circular fashion. The company has won awards at Madrid’s Circular Sustainable Fashion event and gained European recognition.

The Netherlands Between Tradition and Transformation

 A new chapter in Dutch soft-drug policy began with the kick-off of the long-awaited cannabis experiment in early April. However, depending on the outcome policymakers wish to achieve, the solution may lie beyond the coffee shop model.

• Upcoming elections on October 29, 2025, will determine the future of the Netherlands’ coffeeshop model and regulation policy.

Extended photoperiods before harvest can increase cannabis yield without affecting cannabinoid concentration, if limited to two weeks.

• Two weeks of long-day light before harvest can increase inflorescence yield without negatively impacting cannabinoid levels.
• Research on optimizing light conditions for medicinal cannabis growth to standardize active ingredient composition and improve cultivation efficiency.
• Light spectrum used for photoperiod extension does not significantly influence inflorescence yield or cannabinoid concentrations in cannabis.

Italy battles for medical cannabis access equity

Patients present demands for cannabis reform at the Chamber of Deputies. The event aims to address regulatory issues and ensure equitable access to medical cannabis in Italy. Key speakers include Deputy Marianna Ricciardi and medical experts discussing the need for updated legislation and patient education.

While Materia Medica Processing emerges as a national player, the production monopoly remains with the Military Chemical Pharmaceutical Plant in Florence.

 Cannabis-derived terpenes show potential analgesic and anti-inflammatory effects, warranting further clinical research for chronic pain management.

• CBD reduced the severity and frequency of spontaneous recurrent seizures and significantly extended the lifespan of epileptic mice.

Argentina’s Cannabis Sector Caught in Political Crossfire

A presidential decree downgrades several agricultural and statistical agencies, potentially leading to significant public sector layoffs and the sale of state-owned properties. Key organizations affected include INTA, INV, INASE, and the cannabis regulatory agency.

• The dissolution of ARICCAME, made official by Decree 462/2025, represents more than a simple administrative adjustment. It confirms a political and technical failure, leaving the nascent medicinal and industrial cannabis industry without state guidance.
  • Marcelo Morante, a specialist in internal medicine and expert in cannabis and pain, offered his perspective on the national government’s decree. He suggests the reform is a setback that sacrifices rights and comprehensive visions in favor of a more bureaucratic structure.
  • Farmers in the Northwest Province say they are applying for certifications to export, but following the agency’s dissolution, they now face significant uncertainty.
• ANMAT banned several cannabis oils, ointments and an injectable cosmetic product due to safety and regulatory concerns on July 16, 2025.

 Gustavo Valdés launched Caá Cannabis’ first medicinal oil batch for various health conditions, distributed via public hospitals under prescription.

Cannabis sativa extract shows significant anti-parasitic effects against Echinococcus granulosus in vitro and in vivo studies.

Cannabis in France: From Clinical Trials to Cultural Tensions

 Health Technology Assessment is evaluating cannabis-based medicines for potential insurance coverage following the French medical cannabis experiment, with findings expected in early 2026.

 Cannabis users, both occasional and regular, showed consistently lower adherence to COVID-19 public health guidelines for handwashing, mask-wearing, and social distancing among adults in France during the pandemic. This may reflect cognitive impairments, social norms within cannabis-using groups, or broader sociocultural attitudes toward authority and health directives.

Poland’s Cannabis Policy Faces a Turning Point

Parliamentary team proposes legalizing marijuana possession; draft ready, seeking majority support amid challenges from Law and Justice caucus.

Phytopur Bio is introducing the Frosted Lemon Angel (24% THC) variety to pharmacies.

• S-Lab introduces King Sherb, a new medical marijuana variety with 22% THC, now available in Polish pharmacies.

Clinics Replace Dispensaries Under New Rules in Thailand

Ministry of Public Health said that only 2,000 of the estimated 18,000 cannabis shops in Thailand will be left as they will not be able to meet the strict new requirements, when authorities complete their plan to convert dispensaries to clinics with resident doctors by end of 2025.

 Medical cannabis as a substitute for prescription agents: A systematic review and meta-analysis. The study examines the prevalence of medical cannabis as a substitute for prescription agents, and how medical cannabis use impacts the use of other prescription drugs.

• Researchers developed an indirect competitive ELISA assay for quantitative detection of delta-9-tetrahydrocannabinol from Cannabis sativa using Fab antibodies.

Slovenia Legalizes Medical Cannabis Cultivation and Distribution

 Slovenia legalised medical marijuana cultivation, production, and distribution, with a regulated system and a bill for recreational use pending.

• Adults can grow four cannabis plants at home; new regulations proposed for personal use and medical cannabis access. The coalition is also busy implementing the people’s referendum will before going on vacation.

 Argent BioPharma supplies cannabinoid treatment for drug-resistant epilepsy at Slovenia’s largest hospital after successful pilot program, enabling neurologists to dispense recommended, protocol-aligned formulations for young patients.

Turkey’s Medical Cannabis Law Reshapes Access

 Turkish Parliament passes a law that allows controlled sales of low-THC medical cannabis in pharmacies, with oversight by health and agriculture ministries

 Medieval cannabis-infused wine, “drync of Antioche,” was used as a powerful remedy for wounds and is tied to ancient surgical practices. An herbal blend was boiled in a quart of white wine, then combined with an equal amount of clarified honey and simmered into a syrup.

New Zealand’s Cannabis Gets a Reality Check

The Royal Australian & New Zealand College of Psychiatrists (RANZCP) calls for stricter medicinal cannabis regulations to protect vulnerable patients and ensure evidence-based prescribing practices.

• MedSafe released new guidelines on advertising for the unapproved medicine this month which industry players say could put patients at risk.

 The National Business Review online from Cannasource is New Zealand’s leading source for breaking business news and in-depth analysis.

 Cannabis use during immunotherapy may reduce treatment efficacy; further research and caution are needed regarding its use.

Mexico Seeks Clarity on Cannabis Use and Policy

 In a recent article published in Mexico Business News, Raul Elizalde Garza, CEO of HempMeds, provides an exemplary overview of the legal status of marijuana in Mexico.

 Mexico’s Supreme Court decriminalized personal marijuana use, but commercial recreational sales remain illegal. Raúl Elizalde looks at the issue.

 Mexico launches a National Survey on Cannabis Use to gather data for informed, equitable public policies on cannabis regulation.

Georgia’s Cannabis Laws Get a Hard Reset

Georgia’s Parliament is tightening cannabis laws, introducing stricter penalties for possession, cultivation, and sale of marijuana and cannabis plants.

• First-time offenses result in administrative liability, while repeat violations can lead to fines or up to one year imprisonment. Especially large quantities of cannabis can result in severe penalties of up to 20 years imprisonment.

Czech Senate Approves Cannabis Amendment

Senators approved a cannabis legalization amendment; possession of up to 100 grams will be legal, with penalties for larger amounts.

• Supreme State Prosecutor Lenka Bradáčová opposed the amendment, fearing drug dealers would exploit legal loopholes. The Justice Ministry clarified that larger cannabis quantities remain punishable under general drug laws, maintaining accountability for possession.

Colombia’s Push for Legalization as Peace Strategy

 Colombia plans to legalize medical cannabis flower sales through pharmacies, allowing prescriptions for therapeutic use and expanding cultivation licenses.

Lebanon Bets on Cannabis for Economic Revival

 Lebanon’s government promotes legal cannabis cultivation, aiming for economic growth and job creation while ensuring regulatory oversight. The minister believes legal cannabis farming aligns with their national strategy to diversify agricultural production in response to climate, environmental, and food security challenges.

Greece’s Role in Advancing Cannabis Genomics

 Identified genetic variation and sex determination in Cannabis sativa using microsatellite markers and High-resolution melting analysis. The study aims to assess genetic variation by examining morphological and molecular characteristics across 83 different genotypes preserved at Thessaloniki’s Institute of Plant Breeding and Genetic Resources.

Belgium Leads Push for Full-Plant Legality

 EU proposes amendments to hemp regulation, allowing full plant use, ensuring legal clarity, and maintaining public health safeguards. The proposal explicitly confirms that all parts of the hemp plant can be used.

• European Parliament supports hemp legality, aiming for unified EU regulations and ending national bans on cannabis cultivation and use.
• Committee on Herbal Medicinal Products rejects establishing an EU herbal monograph for Cannabis sativa L., flos due to insufficient evidence of safety and efficacy.

North Macedonia’s Cannabis Industry Faces Scrutiny

 Government to review cannabis processing licenses due to abuses, with planned disclosures regarding involved ministers and companies. Investigations revealed that 100kg of cannabis intended for medical use was diverted to the black market.

Andorra’s CBD Case Heads to Europe’s Human Rights Court

 The Constitutional Court (TC) has dismissed the appeal for protection filed by the family of the young man caught at the border with 500 grams of CBD.

• This resolution puts an end to the judicial process within the Principality and opens the door to a possible appeal before the European Court of Human Rights, a path that the family already plans to activate.

Malta’s Cannabis Users Face Warning Letters

 Residents receive warnings from ARUC over cannabis smells, despite unverified complaints; fines introduced for causing nuisance to neighbors. Although the authority maintains it seeks to promote responsible cannabis consumption and foster respect for neighbors, critics argue that the letters overstep legal boundaries.

Navigating Barbados’ Cannabis Reform

Doctors in Barbados can prescribe cannabis but must follow a strict legal process and obtain necessary permissions.

• Recent amendment to the Drug Abuse Prevention and Control Act introduces fixed penalties for minor cannabis offenses. Superintendent Warner emphasizes collaboration between police and community to foster understanding and trust regarding cannabis legislation.

Dominica Eyes Medicinal Cannabis for National Growth

 The Government of Dominica is exploring the vast potential of the cannabis plant to develop a sustainable medicinal cannabis industry on the island, and recognizes that cannabis reform is grounded in science, responsible regulation and broad-based consultations of a national imperative and regional opportunity.

China Maps Genetic Adaptation Through THCAS

 Study identifies THCAS (Δ9-tetrahydrocannabinolic acid synthase) as a key gene influencing UV-B tolerance in cannabis and provides insights into the genomic and molecular mechanisms that govern plant adaptation to UV-B radiation.

South Korea Explores Cannabis Terpenes for Skincare

 Terpene extract from Cannabis sativa shows anti-melanogenetic effects by downregulating melanin content and MITF expression in melan-a cells. Further studies are needed to identify crucial terpenic compounds with anti-melanogenesis inhibitory activity, which would facilitate the use of C. sativa flowers in the cosmetics industry as whitening agents and sources of terpenes.

Peru Monitors Medical Cannabis Safety with New Study

Study analyzes adverse drug reactions from cannabis-based oral solutions in Peru, finding 12.7% reported reactions, mostly mild and early.

Uganda Grants First Experimental Cannabis License

The governmental clearance letter dated July 21, signed by Ugandan Minister of Internal Affairs, Gen (rtd) Kahinda Otafiire, and copied to the Inspector General of Police (IGP), grants an experimental license to the directors of Bright Sparks Farm Limited to venture into the cannabis growing business.

Indonesia Begins Medical Cannabis Research

Head of the National Narcotics Agency (BNN) Komjen Martinus said that medical marijuana legalization research had begun in Indonesia and emphasized that the legalization of marijuana for medical purposes does not necessarily legitimize the use of marijuana freely.

Finland Trials Hemp Hulls in Eco Landscaping

 Harviala is conducting a unique landscaping trial. The company is evaluating hemp bran, a byproduct of oilseed hemp dehusking, as mulch for tree seedlings to prevent weed growth and retain soil moisture.

Uruguay’s Cannabis Faces New Quality Tests

 Research finds link between THC and lead levels in marijuana sold in pharmacies. A doctoral thesis from the Faculty of Chemistry also identified four pesticides in cannabis samples from individuals whose levels meet international standards, but raise “alarms.”

Antigua and Barbuda Intercepts $60,000 Worth of Cannabis

 Police confiscate $60,000 worth of cannabis at Deep Water Harbour. Law enforcement agencies searched the primary seaport, finding a barrel with nineteen vacuum-sealed packages of cannabis, weighing about 7½ pounds. The packages were said to have an estimated street value of EC $60,000.

Lithuania’s Cannabis Lemonade Wins Europe’s Palate

 Lynxmonadas, a Lithuanian cannabis lemonade, wins international awards for quality and design, expanding its market presence in Europe.

Morocco’s Cannabis Reform Faces Headwinds

 Morocco’s legal cannabis industry hampered by bureaucracy, recreational ban and black market appeal. Legal market remains constrained despite 5000 farmers joining the regulated market in 2025.

• The legal cannabis industry grows, but illegal cultivation dominates due to higher profits and strict regulatory hurdles for farmers.

Austria’s Cannabis Sales Stir Debate

 Tobacco shops are allowed to sell low-THC cannabis, which raises concerns about potential health impacts and market monopolies while generating tax revenue.

Ireland Decodes Cannabis Monoecy Locus

 Identified Monoecy1 locus on X chromosome in Cannabis sativa controlling monoecy vs dioecy through three distinct genes’ interactions.

Ukraine Expands Cannabis-Based Medicine Access

 The Ministry of Health of Ukraine has updated the list of dosages for cannabis-based medicines available in the Electronic Healthcare System. 14 THC-based forms and 2 combined forms (THC and CBD) have been added.

Japan’s Data Challenges the Cannabis Gateway Theory

 Cannabis users in Japan show low progression to other drugs, challenging the gateway drug hypothesis based on survey findings.

Ghana Seeks Policy Guidance from Morocco

 Ghana seeks cannabis policy assistance from Morocco, aiming for collaboration on legalization and narcotics control efforts.

Namibia’s Cannabis Ban Faces Grassroots Pushback

 Namibia’s Government has long maintained that the ban on cannabis reflects the will of the people, but a recent Afrobarometer survey shows the opposite is true; Nambians broadly support full-adult use legalization, especially in Caprivi and the north.

Ecuador Launches Premium Hemp Export

 The first two containers of premium hemp biomass have officially arrived at the Port of Miami, and cleared customs in a record-breaking one day.